RCT: Furmonertinib vs. gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)